In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing
- PMID: 28751571
- PMCID: PMC5570639
- DOI: 10.1161/ATVBAHA.117.309881
In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing
Abstract
Objective: High-efficiency genome editing to disrupt therapeutic target genes, such as PCSK9 (proprotein convertase subtilisin/kexin type 9), has been demonstrated in preclinical animal models, but there are safety concerns because of the unpredictable nature of cellular repair of double-strand breaks, as well as off-target mutagenesis. Moreover, precise knock-in of specific nucleotide changes-whether to introduce or to correct gene mutations-has proven to be inefficient in nonproliferating cells in vivo. Base editors comprising CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats [CRISPR]-CRISPR-associated 9) fused to a cytosine deaminase domain can effect the alteration of cytosine bases to thymine bases in genomic DNA in a sequence-specific fashion, without the need for double-strand DNA breaks. The efficacy of base editing has not been established in vivo. The goal of this study was to assess whether in vivo base editing could be used to modify the mouse Pcsk9 gene in a sequence-specific fashion in the liver in adult mice.
Approach and results: We screened base editors for activity in cultured cells, including human-induced pluripotent stem cells. We then delivered a base editor into the livers of adult mice to assess whether it could introduce site-specific nonsense mutations into the Pcsk9 gene. In adult mice, this resulted in substantially reduced plasma PCSK9 protein levels (>50%), as well as reduced plasma cholesterol levels (≈30%). There was no evidence of off-target mutagenesis, either cytosine-to-thymine edits or indels.
Conclusions: These results demonstrate the ability to precisely introduce therapeutically relevant nucleotide variants into the genome in somatic tissues in adult mammals, as well as highlighting a potentially safer alternative to therapeutic genome editing.
Keywords: PCSK9; gene therapy; lipids and lipoprotein metabolism; molecular biology; nucleotides.
© 2017 American Heart Association, Inc.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5570639/bin/nihms893290f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5570639/bin/nihms893290f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5570639/bin/nihms893290f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5570639/bin/nihms893290f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5570639/bin/nihms893290f5.gif)
Similar articles
-
Gene Editing for the Treatment of Hypercholesterolemia.Curr Atheroscler Rep. 2024 May;26(5):139-146. doi: 10.1007/s11883-024-01198-3. Epub 2024 Mar 18. Curr Atheroscler Rep. 2024. PMID: 38498115 Free PMC article. Review.
-
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.BMC Biol. 2019 Jan 15;17(1):4. doi: 10.1186/s12915-018-0624-2. BMC Biol. 2019. PMID: 30646909 Free PMC article.
-
Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.Curr Atheroscler Rep. 2017 Jul;19(7):32. doi: 10.1007/s11883-017-0668-8. Curr Atheroscler Rep. 2017. PMID: 28550381 Free PMC article. Review.
-
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.Arterioscler Thromb Vasc Biol. 2016 May;36(5):783-6. doi: 10.1161/ATVBAHA.116.307227. Epub 2016 Mar 3. Arterioscler Thromb Vasc Biol. 2016. PMID: 26941020 Free PMC article.
-
Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.Circ Res. 2014 Aug 15;115(5):488-92. doi: 10.1161/CIRCRESAHA.115.304351. Epub 2014 Jun 10. Circ Res. 2014. PMID: 24916110 Free PMC article.
Cited by
-
Engineering of a compact, high-fidelity EbCas12a variant that can be packaged with its crRNA into an all-in-one AAV vector delivery system.PLoS Biol. 2024 May 30;22(5):e3002619. doi: 10.1371/journal.pbio.3002619. eCollection 2024 May. PLoS Biol. 2024. PMID: 38814985 Free PMC article.
-
Breaking genetic shackles: The advance of base editing in genetic disorder treatment.Front Pharmacol. 2024 Mar 6;15:1364135. doi: 10.3389/fphar.2024.1364135. eCollection 2024. Front Pharmacol. 2024. PMID: 38510648 Free PMC article. Review.
-
Gene Editing for the Treatment of Hypercholesterolemia.Curr Atheroscler Rep. 2024 May;26(5):139-146. doi: 10.1007/s11883-024-01198-3. Epub 2024 Mar 18. Curr Atheroscler Rep. 2024. PMID: 38498115 Free PMC article. Review.
-
Phage-assisted evolution of highly active cytosine base editors with enhanced selectivity and minimal sequence context preference.Nat Commun. 2024 Feb 24;15(1):1697. doi: 10.1038/s41467-024-45969-7. Nat Commun. 2024. PMID: 38402281 Free PMC article.
-
Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo.Mol Ther Nucleic Acids. 2023 Dec 27;35(1):102112. doi: 10.1016/j.omtn.2023.102112. eCollection 2024 Mar 12. Mol Ther Nucleic Acids. 2023. PMID: 38292874 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous